Tumor Board Tuesday Evaluation April 6, 2021 - Present (ID: i788-10)

Question Title

* 1. What is your degree?

MD/DO

Pharmacist

Nurse

Other (please specify)

Question Title

* 2. What is your specialty?

Med/Surg/Rad/IR Onc

Other MD, APP, RN, PharmD

Patient/Patient Advocate

Fellow, Resident, Trainee

Question Title

* 3. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 4. How many patients with advanced or metastatic cancers do you treat each week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 5. Please select the option that best describes your practice:

Academic Clinician

Community Clinician

Other (please specify)

Question Title

* 6. After participating in these activities, I am now able to:

Elucidate the genomic, immunogenic, and proteomic aberrations that serve as molecular drivers for a wide variety of solid tumors and mandate the necessity for a personalized approach to treatment

Select personalized treatments for patients with breast, gastrointestinal, genitourinary, and lung cancer based on the characteristics of each patient and the molecular profile of each tumor

Assess treatments currently in late-phase development that are being studied for their ability to address actionable molecular targets common to disease state subsets within breast, gastrointestinal, genitourinary, and lung cancers

Question Title

* 7. The content presented:

Enhanced my current knowledge base

Addressed my most pressing questions

Promoted improvements or quality in health care

Was scientifically rigorous and evidence based

Question Title

* 8. These activities were free from commercial bias.

Yes

Question Title

* 9. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 10. Which new strategies/skills/information will you apply to your area of practice? Select all that apply

Be better at understanding molecular alterations in advanced or metastatic cancers and their impact on therapeutic decision making.

Be better able to utilize best practices when transitioning therapies.

Elucidate the genomic, immunogenic, and proteomic aberrations that serve as molecular drivers for a wide variety of solid tumors.

Mandate the necessity for a personalized approach to treatment when dealing with solid tumors.

Select personalized treatments for patients with breast, gastrointestinal, genitourinary, and lung cancer based on the characteristics of each patient and the molecular profile of each tumor.

Question Title

* 11. How committed are you to making changes in your practice based on your participation in these activities?

Very Committed

Committed

Neutral

Not committed

I do not plan to make changes

Question Title

* 12. As a result of your participation in these activities, what is the one change you are most likely to implement in your practice?

Question Title

* 13. What barriers do you see to making changes in your practice? Select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resource to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines and/or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:

Question Title

* 15. Please select the number of conversations below that you attended and wish to claim credit for:

I participated in 1 conversation and claim 1 credit.

I participated in 2 conversations and claim 2 credits.

I participated in 3 conversations and claim 3 credits.

I participated in 4 conversations and claim 4 credits.

I participated in 5 conversations and claim 5 credits.

I participated in 6 conversation and claim 6 credits.

I participated in 7 conversations and claim 7 credits.

I participated in 8 conversations and claim 8 credits.

I participated in 9 conversations and claim 9 credits.

I participated in 10 conversations and claim 10 credits.

I participated in 11 conversations and claim 11 credits.

I participated in 12 conversations and claim 12 credits.

I participated in 13 conversations and claim 13 credits.

I participated in 14 conversations and claim 14 credits.

I participated in 15 conversations and claim 15 credits.

I participated in 16 conversations and claim 16 credits.

I participated in 17 conversations and claim 17 credits.

I participated in 18 conversations and claim 18 credits.

Question Title

* 16. To receive CME credit for completing these activities, please provide your full name, contact information, and submit this completed evaluation form:

Name

Degree & Specialty

State/Province

Email Address